H.C. Wainwright lowered the firm’s price target on Cognition Therapeutics (CGTX) to $5 from $6 and keeps a Buy rating on the shares. The firm expects a “somewhat lengthened path” to market for zervimesine.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX: